Scarica l'app Stockscreener
3.72
2.76%
0.10
Precedente Chiudi:
$3.62
Aprire:
$3.74
Volume 24 ore:
664.91K
Relative Volume:
1.19
Capitalizzazione di mercato:
$224.77M
Reddito:
$40.37M
Utile/perdita netta:
$-119.72M
Rapporto P/E:
-1.8234
EPS:
-2.0402
Flusso di cassa netto:
$-135.06M
1 W Prestazione:
+7.51%
1M Prestazione:
+5.38%
6M Prestazione:
-9.71%
1 anno Prestazione:
+22.37%
Intervallo 1D:
$3.665
$3.801
Intervallo di 1 settimana:
$3.43
$3.801
Portata 52W:
$2.83
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Nome
Voyager Therapeutics Inc
Settore
Industria
Telefono
857-259-5340
Indirizzo
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.72 | 224.77M | 40.37M | -119.72M | -135.06M | -2.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-02 | Iniziato | Citigroup | Buy |
| 2024-11-29 | Ripresa | Wedbush | Outperform |
| 2024-10-16 | Iniziato | Leerink Partners | Outperform |
| 2024-03-26 | Iniziato | Guggenheim | Buy |
| 2024-03-19 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-07 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | Iniziato | Truist | Buy |
| 2023-03-10 | Iniziato | Oppenheimer | Outperform |
| 2021-10-07 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | Downgrade | BTIG Research | Buy → Neutral |
| 2021-02-03 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-11-10 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | Iniziato | The Benchmark Company | Buy |
| 2020-02-06 | Iniziato | Oppenheimer | Outperform |
| 2018-11-15 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-09-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-02-02 | Iniziato | Morgan Stanley | Overweight |
| 2017-11-28 | Ripresa | Piper Jaffray | Overweight |
| 2017-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2017-10-27 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-23 | Reiterato | Stifel | Buy |
| 2017-10-12 | Iniziato | Raymond James | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-28 | Ripresa | Stifel | Buy |
Mostra tutto
Voyager Therapeutics Inc Borsa (VYGR) Ultime notizie
Voyager Therapeutics Inc (VYGR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Voyager Therapeutics Inc (VYGR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Voyager Therapeutics Inc (VYGR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Voyager Therapeutics Inc (VYGR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Voyager Therapeutics, Inc. Stock 12‑Month Price Target Raised to $15.38, Implies 325% Upside - TradingView
Voyager Therapeutics Inc (VYGR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Voyager Therapeutics Inc (VYGR) Institutional Confidence - TradingKey
Voyager Therapeutics Inc (VYGR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Voyager Therapeutics Inc (VYGR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Voyager Therapeutics Inc (VYGR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference - markets.businessinsider.com
Voyager Therapeutics (VYGR) director awarded 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics (VYGR) grants director 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics director granted 30,000 options | VYGR Insider Trading - Stock Titan
Voyager director granted options for 30,000 shares | VYGR Insider Trading - Stock Titan
Voyager Therapeutics (VYGR) director receives 30,000 stock options grant - Stock Titan
Voyager Therapeutics (VYGR) director granted 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics (VYGR) grants director Glenn Pierce 30,000 stock options - Stock Titan
Voyager Therapeutics Expands Authorized Shares After Stockholder Vote - TipRanks
Voyager Therapeutics (NASDAQ: VYGR) doubles authorized common stock after 2026 vote - Stock Titan
Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation - Yahoo Finance
Guggenheim Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Voyager’s tau-targeted gene therapy VY-1706 gains IND approval - BioWorld News
Voyager gets FDA clearance for Alzheimer’s gene therapy trial By Investing.com - Investing.com India
Voyager Therapeutics (VYGR) Gains FDA Approval for Alzheimer's G - GuruFocus
Voyager Therapeutics Receives FDA Clearance to Begin Clinical Trial of VY1706 Gene Therapy for Alzheimer’s Disease - Minichart
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease - markets.businessinsider.com
Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy - TipRanks
Voyager Therapeutics receives FDA clearance to begin Alzheimer’s gene therapy trial - Investing.com India
FDA clears Voyager Therapeutics (VYGR) IND for Alzheimer’s gene therapy VY1706 - Stock Titan
Voyager Receives FDA IND Clearance for VY1706, First Gene - GlobeNewswire
Voyager Therapeutics Announces Fda Clearance of Investigational New Drug Application for Vy1706 for Alzheimer's Disease - marketscreener.com
Voyager Therapeutics Stock Is Waking Up Before a Make-or-Break Tau Window - Bez Kabli
H.C. Wainwright Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
H.C. Wainwright reiterates Voyager Therapeutics stock rating on pipeline progress - Investing.com Australia
H.C. Wainwright reiterates Voyager Therapeutics stock rating on pipeline progress By Investing.com - Investing.com South Africa
Voyager Therapeutics Q1 2026 Earnings: Narrower‑than‑Expected Loss Drives Positive Stock Reaction - The Legal Advocate
Voyager Therapeutics Inc. (VYGR) Q1 2026 Earnings: Narrowed Loss Meets Optimism in Gene Therapy PipelineEPS Consistency Score - Newser
Voyager Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ResponseNet Income Trends - Newser
Voyager Therapeutics (VYGR) Shares Rebound 4.76% as Biotech Sector Shows StrengthCrowd Risk Alerts - Newser
- Insider Monkey
What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs - Insider Monkey
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Voyager Therapeutics (VYGR) accounting officer reports initial share and option holdings - Stock Titan
The one question every Voyager Therapeutics VYGR investor should ask Bullish Sentiment 20260510Weak Earnings Momentum - The Legal Advocate
VYGR (NASDAQ: VYGR) affiliate files Form 144 to sell 25,000 shares - Stock Titan
EcoR1 and Oleg Nodelman report 0 shares in Voyager (NASDAQ: VYGR) amendment - Stock Titan
Armistice Capital (VYGR) reports 3.5M shares, 5.87% stake in Voyager - Stock Titan
Voyager Therapeutics (NASDAQ: VYGR) affiliate files to sell 9,406 shares - Stock Titan
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8 - Moomoo
TradingKey - TradingKey
Voyager Therapeutics Inc Azioni (VYGR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):